丙丁酚治疗非增殖性糖尿病视网膜病变的临床观察
Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy
摘要: 目的：观察丙丁酚治疗非增殖性糖尿病视网膜病变(NPDR)的临床疗效。方法：于2012年1月至2013年8月选取非增殖性糖尿病视网膜病变患者68例作为研究对象，再将非增殖性糖尿病视网膜病变(NPDR)患者分为四组：即：A组、强化治疗+丙丁酚组，共17例；B组、强化治疗组，共17例；C组、常规治疗 + 丙丁酚组，共17例；D组、常规治疗组，共17例，避免服用其它抗氧化剂。A、C组DR患者予丙丁酚0.375 g，每日2次。平均随访11.58 ± 0.17个月。并比较观察4组干预前、1年后的视力、眼底及血脂(TC、LDLC)变化。结果：最终随访发现：1、A、C组NPDR患者的眼底情况较干预前显著改善(P < 0.05)，A、C组间干预后眼底情况无显著性差异(P > 0.05)；B、D组患者的眼底情况均无显著改善(P > 0.05)。2、A、C组患者最佳矫正视力均较干预前显著提高(P < 0.05)，A、C组间干预后最佳矫正视力无显著性差异(P > 0.05)；B、D组患者最佳矫正视力均无显著提高(P > 0.05)。3、A、C组患者TC、LDLC水平均显著低于干预前(P < 0.05)；B、D组干预前后血脂水平无显著性差异(P > 0.05)；且干预后A、C组间TC、LDLC水平无显著性差异(P > 0.05)。结论 丙丁酚治疗非增殖性糖尿病视网膜病变疗效显著，且并发症较少。
Abstract: Objective: To observe the clinical efficacy of probucol for nonproliferative diabetic retinopathy (NPDR). Methods: 68 patients with nonproliferative diabetic retinopathy (NPDR) were studied from Jan. 2012 to Aug. 2013. These patients were divided into four groups. Group A consisted of 17 patients receiving enhanced therapy and probucol; Group B consisted of 17 patients receiving enhanced therapy; Group C consisted of 17 patients receiving regular therapy and probucol; Group D consisted of 17 patients receiving regular therapy. Group A and Group C were given probucol of 0.375 g twice per day. All patients were followed up for average 11.58 ± 0.17 months. The changes of best corrected visual acuity, fundus, total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) before therapy and one year after therapy were observed. Results: 1) The fundi of Group A and Group C were significantly improved (P < 0.05), and there was no significant difference between the fundi of Group A and of Group C after therapy (P > 0.05); but the difference between the fundi of Group B and of Group D was not statistically significant (P > 0.05). 2) The best corrected visual acuity of Group A and Group C was improved significantly (P < 0.05), and there was no significant difference between the best corrected visual acuity of Group A and of Group C (P > 0.05); but the best corrected visual acuity of Group B and Group D did not change significantly (P > 0.05). 3) The TC and LDLC level of Group A and Group C decreased significantly (P < 0.05); The TC and LDLC level of Group B and Group D did not change significantly (P > 0.05); There was no significant difference between the TC and LDLC level of Group A and of Group C (P > 0.05). Conclusion: The efficacy of probucol for nonproliferative diabetic retinopathy is significant with less complications.
文章引用：蒋苏平, 陈忠平. 丙丁酚治疗非增殖性糖尿病视网膜病变的临床观察[J]. 眼科学, 2014, 3(2): 13-18. https://dx.doi.org/10.12677/HJO.2014.32003

参考文献

[1] Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820.
[2] Virag, L. and Szabó, C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacological Reviews, 54, 375-429.
[3] Obrosova, I.G., Pacher, P., Szabo, C., et al. (2005) Aldose reductase in-hibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes, 54, 234-242.
[4] Yokoi, M., Yamagishi, S., Takeuchi, M., et al. (2005) Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. British Journal of Ophthalmology, 89, 673-675.
[5] Kowluru, R.A., Tang, J. and Kern, T.S. (2001) Abnormalities of retinal metabolism in diabetes and experimental galactosemia VII. Effect of long-term adm inistration of antioxidants on the development of retinopathy. Diabetes, 50, 1938-1942.
[6] Rema, M., Srivastava, B.K., Anitha, B., et al. (2006) Association of serum lipids with diabetic retinopathy in urban South Indians—The Chennai Urban Rural Epidemiology Study (CURES) Eye Study—2. Diabetic Medicine, 23, 1029-36.
[7] 廖璞, 王淑琴, 王宁等 (2003) NF-Kp在糖尿病大鼠肾脏和血液单个核细胞中的表达. 基础医学与临床, 3, 328-331.
[8] 王拥军 (2001) 应加强颈动脉粥样硬化的基础和临床研究. 中华神经科杂志, 5, 257.
[9] Du, Y., Miller, C.M. and Kem, T.S. (2003) Hyperglycemia increases mi-tochondrial superoxide in retina and retinal cells. Free Radical Biology Medicine, 35, 1491-1499.
[10] Kowaltowski, A.J., Castilho, R.F. and Vercesi, A.E. (2001) Mitochondrial permeabilitytransition and oxidative stress. FEBS Letters, 495, 12-15.
[11] 陈永东, 许讯 (2007) 氧化应激在糖尿病视网膜病变中的作用研究进展. 中华眼底病杂志, 23, 298-300.
[12] O’Leary, V.J., Tilling, L., Fleetwood, G., et al. (1996) The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy. Atherosclerosis, 119, 169-179.
[13] Bamhart, R.L., Busch, S.J. and Jackson, R.L. (1989) Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro:probucol degradation Precedes lipoprotein oxidation. The Journal of Lipid Research, 30, 1703-1710.
[14] Baumstark, M.W., Aristegui, R., Zoller, T., et al. (1992) Probucol, incorporated into LDL particles in vivo, inhibits generation of lipid peroxides more effectively than endogenous antioxidants alone. Clinical Biochemistry, 25, 395-397.
[15] Masana, L., Bargallo, M.T., Plana, N., et al. (1991) Effeetiveness of probucol inreducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. American Journal of Cardiology, 68, 863-867.

为你推荐